Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

Recruiting N/A Interventional Study
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection Hemolytic-Uremic Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
9 Months – 21
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
1,040 (estimated)
Sponsor
University of Calgary · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: In order to be eligible to participate in this study (i.e., to be enrolled in the relevant institutional clinical care pathway), an individual must meet all of the following criteria: 1. Aged 9.0 months to \<21 years at the time of informed consent. 2. Evidence of high-risk STE…
Contacts

Study Manager

(801) 581-6410

hikostec@hsc.utah.edu

CONTACT